Dongkook Pharmaceutical (086450) stock
KOSDAQ · Pharmaceuticals
As of Nov 16, 1:11 PM KST
- Market cap
- KRW 997.3 billion
- As of Nov 16, 2026
- P/E
- 14.31x
- Trailing twelve months
- P/B
- 1.47x
- Latest reported equity
- P/S
- 0.99x
- Trailing twelve months
- ROE
- 10.3%
- Trailing twelve months
- Dividend yield
- 0.91%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 997.3 billion
- As of Nov 16, 2026
- P/E
- 14.31x
- Trailing twelve months
- P/B
- 1.47x
- Latest reported equity
- P/S
- 0.99x
- Trailing twelve months
- ROE
- 10.3%
- Trailing twelve months
- Dividend yield
- 0.91%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
14.31x
P/B
1.47x
P/S
0.99x
Earnings and dividend metrics▾
Earnings
EPS
KRW 1,541
Earnings per share
BPS
KRW 15,018
Book value per share
ROE
10.3%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 1,541 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 15,018 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 10.3%.
Dividends
1 observed in the last year · Record dates: Dec
Yield
0.91%
Dividend per share
KRW 200
Payout ratio
13.7%
Consecutive years
4+ yrs
Yield uses dividends observed over the last year (by record date) · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about KRW 20,000 before tax.
- Payout ratio — 13.7% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 4 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 258.9 billion | KRW 26.1 billion | KRW 17.2 billion | +10.9% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 251 billion | KRW 27.3 billion | KRW 26.3 billion | +12.2% |
| Q4 2025Consolidated · Filed Mar 12, 2026 | KRW 242.9 billion | KRW 24.3 billion | KRW 15.6 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 226.8 billion | KRW 24.8 billion | KRW 22.3 billion | +12.9% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 233.5 billion | KRW 22.1 billion | KRW 18.1 billion | +14.7% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 223.7 billion | KRW 25.3 billion | KRW 18 billion | +13.7% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 12, 2026 | KRW 926.9 billion | KRW 96.6 billion | KRW 73.9 billion | — |
| FY2024Consolidated · Filed Mar 13, 2025 | KRW 812.2 billion | KRW 80.4 billion | KRW 62.3 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 3.56%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 490 million
- Previous 20-day average 4.78%
- Net short position
- 163,435 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 4,263,536 shares
- As of Nov 13, 2026 · 9.43% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 3.56% | KRW 490 million |
| Nov 12, 2026 | 10.26% | KRW 1 billion |
| Nov 11, 2026 | 7.44% | KRW 940 million |
| Nov 10, 2026 | 2.43% | KRW 250 million |
| Nov 9, 2026 | 2.98% | KRW 260 million |
| Nov 6, 2026 | 3.04% | KRW 270 million |
| Nov 5, 2026 | 2.00% | KRW 360 million |
| Nov 4, 2026 | 4.20% | KRW 410 million |
| Nov 3, 2026 | 5.29% | KRW 900 million |
| Nov 2, 2026 | 7.91% | KRW 820 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Shareholders Meeting(Korean)Nov 12, 2026
- Resolution to Convene a Shareholders Meeting (Extraordinary General Meeting)Oct 12, 2026 · Shareholders MeetingEnglish
- Report on Major Holdings of Shares (General Form)(Korean)May 26, 2026 · Major Holding Report
- Results of Annual General Meeting(Korean)Mar 20, 2026 · Shareholders Meeting
- Resolution to Convene a Shareholders Meeting(Korean)Feb 12, 2026 · Shareholders Meeting
- Decision on Cash or In-kind Dividend(Korean)Feb 5, 2026 · Dividend
- Record Date for Cash or In-kind Dividend(Korean)Dec 12, 2025 · Dividend
- Decision on Treasury Share Disposal(Korean)Dec 11, 2025 · Treasury Share Disposal
Filings with a published English version open in English; the rest link to the Korean original.
Dongkook Pharmaceutical (086450) stock information
KOSDAQ
Dongkook Pharmaceutical (086450) is listed on KOSDAQ. Its market capitalization is about KRW 997.3 billion. On trailing-twelve-month earnings the P/E ratio is 14.31, and the P/B ratio is 1.47. Return on equity is 10.3%. These figures are computed in-house from official filings and are reference information only.
Dongkook Pharmaceutical — frequently asked questions
- What is the P/E ratio of Dongkook Pharmaceutical (086450)?
- On a trailing-twelve-month basis, 086450 trades at a P/E ratio of 14.31. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Dongkook Pharmaceutical?
- 086450 has a market capitalization of about KRW 997.3 billion. The figure moves with the share price and is refreshed each trading day.
- Does Dongkook Pharmaceutical pay a dividend?
- 086450 has a dividend yield of about 0.91%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.